Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K.

Clin Cancer Res. 2017 Dec 1;23(23):7288-7300. doi: 10.1158/1078-0432.CCR-17-1544. Epub 2017 Sep 25.

2.

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.

Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK.

J Cancer. 2017 Jul 5;8(11):2004-2009. doi: 10.7150/jca.18196. eCollection 2017.

3.

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.

Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K.

Nat Commun. 2017 Jun 27;8:15916. doi: 10.1038/ncomms15916.

4.

Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.

Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K.

Cancer Res. 2016 Apr 15;76(8):2406-18. doi: 10.1158/0008-5472.CAN-15-1646. Epub 2016 Feb 29.

5.

Evaluation of ARG protein expression in mature B cell lymphomas compared to non-neoplastic reactive lymph node.

Kabiri Z, Salehi M, Mokarian F, Mohajeri MR, Mahmoodi F, Keyhanian K, Doostan I, Ataollahi MR, Modarressi MH.

Cell Immunol. 2009;259(2):111-6. doi: 10.1016/j.cellimm.2009.06.004. Epub 2009 Jun 6.

PMID:
19604504
6.

Bcl-2 associated athanogene-1 overexpression in diffuse large B-cell lymphoma.

Ataollahi M, Salehi M, Doostan I, Kabiri Z, Mohajeri M, Mahmoodi F, Shokouhi R, Javan S, Meshkibaf MH, Miladpoor B.

Iran J Immunol. 2008 Jun;5(2):124-30. doi: IJIv5i2A7.

Supplemental Content

Loading ...
Support Center